Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Camp4 Therapeutics Corp (CAMP)

Camp4 Therapeutics Corp (CAMP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 268,159
  • Shares Outstanding, K 46,881
  • Annual Sales, $ 650 K
  • Annual Income, $ -51,790 K
  • EBIT $ -54 M
  • EBITDA $ -53 M
  • 60-Month Beta 1.28
  • Price/Sales 330.76
  • Price/Cash Flow N/A
  • Price/Book 3.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.35
  • Number of Estimates 5
  • High Estimate -0.28
  • Low Estimate -0.56
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.90 +107.24%
on 11/24/25
6.10 -1.48%
on 12/11/25
+1.88 (+45.52%)
since 11/11/25
3-Month
2.20 +173.18%
on 09/19/25
6.10 -1.48%
on 12/11/25
+3.23 (+116.19%)
since 09/11/25
52-Week
1.30 +360.54%
on 06/20/25
9.77 -38.49%
on 12/12/24
-2.47 (-29.13%)
since 12/11/24

Most Recent Stories

More News
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation  (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline...

CAMP : 6.08 (+6.29%)
CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights

Strengthened balance sheet with private placement of up to $100 million to advance CMP-002, a first-in-class treatment for SYNGAP1-related disorders  Initiated Good Laboratory Practice (GLP) toxicology...

CAMP : 6.08 (+6.29%)
3 Healthcare Companies Insiders Are Buying 

Insiders are buying these three healthcare companies that have catalysts to drive their share prices higher in the upcoming years.

SI : 14.67 (-0.95%)
LLY : 1,015.34 (+2.18%)
CAMP : 6.08 (+6.29%)
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01

CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation  (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline...

CAMP : 6.08 (+6.29%)
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

Oversubscribed Financing led by Coastlands Capital with participation from new and existing investors Financing to provide $50 million in upfront proceeds with the potential for up to an additional...

CAMP : 6.08 (+6.29%)
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

Presented positive translational data from SYNGAP1-related disorders program showcasing efficacy in a humanized SYNGAP mouse model and increased protein in non-human primates at the 28 th American...

CAMP : 6.08 (+6.29%)
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th...

CAMP : 6.08 (+6.29%)
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

CAMP : 6.08 (+6.29%)
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

CAMP : 6.08 (+6.29%)
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

CAMP : 6.08 (+6.29%)

Business Summary

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases. CAMP4 Therapeutics Corporation is based...

See More

Key Turning Points

3rd Resistance Point 7.85
2nd Resistance Point 6.90
1st Resistance Point 6.31
Last Price 6.08
1st Support Level 4.77
2nd Support Level 3.82
3rd Support Level 3.23

See More

52-Week High 9.77
Fibonacci 61.8% 6.54
Last Price 6.08
Fibonacci 50% 5.54
Fibonacci 38.2% 4.54
52-Week Low 1.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar